FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March of 2024. Royalty Pharma had acquired an interest in PureTech's royalty in KarXT.
Wall Street rose this afternoon after better than expected inflation figures cleared the way for the US Federal Reserve to ...
PureTech Systems Inc., the leader in geospatial AI-boosted video analytics for wide-area perimeter and border security, is ...
PureActiv will deploy across multiple locations to detect unauthorized access as ships travel through the waterway system.
Andrew Miller, then an executive at PureTech Health, licensed xanomeline in 2012 and founded Karuna to develop the treatment. Karuna solved the side effect problem by adding trospium, a muscarinic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback